Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 1
2010 1
2011 1
2015 1
2017 1
2018 2
2020 1
2021 1
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers.
Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, Cons L, Lesnier A, Chatel L, Papaioannou A, Salgado-Pires S, Krämer S, Gockel I, Lordick F, Masternak K, Poitevin Y, Magistrelli G, Malinge P, Shang L, Kallendrusch S, Strein K, Hose D. Seckinger A, et al. Among authors: masternak k. J Hematol Oncol. 2023 Dec 12;16(1):117. doi: 10.1186/s13045-023-01516-3. J Hematol Oncol. 2023. PMID: 38087365 Free PMC article.
Selective CD47 targeting with a bispecific antibody.
Ferlin W, Masternak K, Shang L. Ferlin W, et al. Among authors: masternak k. Cancer Immunol Immunother. 2021 Apr;70(4):1161-1162. doi: 10.1007/s00262-020-02812-4. Epub 2021 Jan 2. Cancer Immunol Immunother. 2021. PMID: 33388996 Free PMC article. No abstract available.
CCR7 is involved in the migration of neutrophils to lymph nodes.
Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML, Magistrelli G, Masternak K, Chevailler A, Delneste Y, Jeannin P. Beauvillain C, et al. Among authors: masternak k. Blood. 2011 Jan 27;117(4):1196-204. doi: 10.1182/blood-2009-11-254490. Epub 2010 Nov 4. Blood. 2011. PMID: 21051556 Free article.
Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.
Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, Broyer L, D'Asaro M, Matthes T, LeGallou S, Fest T, Tarte K, Clarke Hinojosa RK, Genescà Ferrer E, Ribera JM, Dey A, Bailey K, Fielding AK, Eissenberg L, Ritchey J, Rettig M, DiPersio JF, Kosco-Vilbois MH, Masternak K, Fischer N, Shang L, Ferlin WG. Buatois V, et al. Among authors: masternak k. Mol Cancer Ther. 2018 Aug;17(8):1739-1751. doi: 10.1158/1535-7163.MCT-17-1095. Epub 2018 May 9. Mol Cancer Ther. 2018. PMID: 29743205 Free PMC article.
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors.
Hatterer E, Chauchet X, Richard F, Barba L, Moine V, Chatel L, Broyer L, Pontini G, Bautzova T, Juan F, Calloud S, Bosson N, Charreton M, Masternak K, Buatois V, Shang L. Hatterer E, et al. Among authors: masternak k. MAbs. 2020 Jan-Dec;12(1):1739408. doi: 10.1080/19420862.2020.1739408. MAbs. 2020. PMID: 32191151 Free PMC article.
16 results